Fibroid is the most common benign tumour of the uterus affecting 20% of women of reproductive age group. The symptoms include menstrual disturbances, commonly menorrhagia and dysmenorrhea. Mifepristone on the other hand is a progesterone receptor modulator with mainly antagonistic properties.This study was done to study the effect of 25 mg Mifepristone daily for 3 months on improvement of fibroid related symptoms and on the size of uterine fibroid and evaluate the side-effects of Mifepristone.
Materials and Method: This clinical study compared the role of low dose mifepristone in the management of uterine fibroid. The total sample size was determined to be 100 patients of age 18-49 years. Uterine volume, volume of the fibroid, their number and size was assessed by performing abdominal or transvaginal sonography at baseline, one month and 3 months.
Results: The mean age of the study population was 39.17±6.67 (18-49) years. Menorrhagia was the predominant symptom among 54.0%. Majority (63.0%) of the subjects had Intra-mural fibroid. The mean PBAC score and Numeric Pain Rating Scale score decreased significantly from baseline to 1 month to 3 months. The mean uterine volume, Volume of the fibroid decreased and endometrial thickness increased significantly from baseline to 1 month to 3 months. The mean Hb level increased significantly from baseline to 1 month to 3 months.
Conclusion: It can be concluded that at the end of 3 months, there was significant reduction in the amount of menorrhagia, dysmenorrhea, abdominal pain, uterine and fibroid volume and improvement in haemoglobin level.